Change in management structure at Santen Ltd

Article

Santen Pharmaceutical Co., Ltd., the Japanes ophthalmic pharmaceutical company, has announced that Adrienne Graves, PhD, president and chief executive officer (CEO) of its wholly-owned US subsidiary, Santen Inc., has resigned...

Santen Pharmaceutical Co., Ltd., the Japanes ophthalmic pharmaceutical company, has announced that Adrienne Graves, PhD, president and chief executive officer (CEO) of its wholly-owned US subsidiary, Santen Inc., has resigned and will continue to work with Santen as a strategic consultant and advisor to the Senior Management of Santen. Regarding the change, Mr. Akira Kurokawa, President and CEO of Santen Ltd., noted: “Dr. Graves built a strong US team, was responsible for obtaining three NDA approvals and is an active member on the boards of many ophthalmic organizations. We look forward to Adrienne’s continued contribution to Santen’s globalization initiatives as a strategic advisor on the development of the US market.”

With effect from April 1, 2010 Toshiaki Nishihata, PhD will become the CEO of Santen Inc. in addition to continuing in his current role as a Member of the Board, Senior Corporate Officer and Head of the Research and Development Division. Akihiro Tsujimura, who most recently was the Head of Business Development Department, will become the Chief Operating Officer (COO) of Santen Inc.

Mr Kurokawa noted that this change in management structure will support the increased focus on the US market as part of Santen's globalization initiative. “We are focused on building a robust global pipeline, particularly in support of an increased presence in the US market, and we are aggressively expanding our clinical and business development efforts to support the company's international expansion. This change in management structure will increase the communication and corporate focus on the US market,” stated Mr Kurokawa.

“The R&D staff at Santen Inc. will remain an integral part of our overall global efforts. They are an essential element as we advance our R&D initiatives. I am eager to take on this new role and lead the company to enhance our global, integrated approach to R&D,” Dr Nishihata commented.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.